Holen Sie sich die Stockscreener-App
1,133.00
2.41%
-27.95
Handel nachbörslich:
1134.00
1.00
+0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Jayp - GuruFocus
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - AOL.com
Eli Lilly & Co. Stock (US5324571083): Weekly technical picture in focus - AD HOC NEWS
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - The Motley Fool
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - Investing News Network
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - investor.lilly.com
Eli Lilly & Co. Stock (US5324571083): Novo Nordisk peer check keeps obesity drug leader in focus - AD HOC NEWS
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? - Insider Monkey
Lilly trial drug cuts spleen size, symptoms in myelofibrosis - Stock Titan
Jim Cramer Wasn’t Selling Eli Lilly (LLY) - Insider Monkey
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Abridge Secures Strategic Investment From Eli Lilly, Expands AI Platform Into Payer and Research Workflows - Digital Health News
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Australia
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Is Eli Lilly's Growth Story Still Gaining Strength? - Kalkine Media
Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth - Yahoo Finance
The Catch Hiding In Eli Lilly Stock’s Growth Story - Trefis
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - Yahoo Finance
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance - Insider Monkey
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy - 24/7 Wall St.
Prometheus raises $12 billion in capital for artificial engineers - statnews.com
Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline - Insider Monkey
Eli Lilly and Company $LLY is Xponance LLC's 10th Largest Position - MarketBeat
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Eli Lilly donates $50,000 to Kenosha YMCA for teen services - Kenosha News
Polen Capital Management LLC Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Kovack Advisors Inc. Purchases 3,506 Shares of Eli Lilly and Company $LLY - MarketBeat
IFM Investors Pty Ltd Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Boosted by Parnassus Investments LLC - MarketBeat
Nuveen LLC Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
The Catch Hiding In Eli Lilly Stock's Growth Story - Trefis
Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies - Insider Monkey
Eli Lilly Stock Outlook 2026: The Retatrutide Upgrade Cycle - EBC Financial Group
Insider Sell: Ilya Yuffa Sells 2,500 Shares of Eli Lilly and Co (LLY) - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 2.2%What's Next? - MarketBeat
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly (NYSE: LLY) EVP Ilya Yuffa sells 2,500 shares in 10b5-1 trade - Stock Titan
Abridge inks deals with Nvidia and Lilly - statnews.com
Abridge is becoming the operating system for medicine after landing Eli Lilly equity and a clinical foundation model deal with NVIDIA - Startup Fortune
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy - Yahoo Finance
Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it - Fortune
Accelerating Speed to Patient: A Conversation With Eli Lilly’s Sarah O’Keeffe - Pharmaceutical Executive
Abridge picks up strategic investment from Eli Lilly, expands payer, research workflows - Fierce Healthcare
Eli Lilly (LLY) Faces Coverage Challenges for GLP-1 Weight Loss Drugs - GuruFocus
Eli Lilly (LLY) Stock Climbs on Explosive Weight Loss Drug Demand and 56% Sales Growth - FXLeaders
AlzeCure inks Alzheimer's deal with Eli Lilly - BioXconomy
Eli Lilly & Co (NYSE:LLY): An Affordable Growth Opportunity in the Pharmaceutical Sector - ChartMill
Saturna Capital Corp Sells 28,164 Shares of Eli Lilly and Company $LLY - MarketBeat
Sharpepoint LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Dorsey & Whitney Trust CO LLC Sells 4,020 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company - Britannica
Eli Lilly Wins Court Order in Fraud Allegations Against Florida, TN Pharmacy Groups - Insurance Journal
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story - Yahoo Finance
Eli Lilly stock (US5324571083): Latest catalyst in focus - AD HOC NEWS
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement - Pharmaceutical Technology
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis - BioWorld News
[144] ELI LILLY & Co SEC Filing - Stock Titan
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care - Yahoo Finance
Eli Lilly stock (US5324571083): Alzheimer’s deal and obesity boom keep momentum in focus - AD HOC NEWS
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon - Reuters
AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly - Pharmaceutical Executive
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,300 to $1,500 - Moomoo
1.07%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):